“MEDEZE” Showcases Strong Stem Cell Business Performance in Q1 2026 at Earnings Call (Opp Day) Advancing Research and Expanding Franchise Network to Drive Long-Term Growth
Ms. Anchisa Lekphet (right), Chief Accounting and Financial Officer, and Dr. Vasawat Sroithong (left), Investor Relations Officer of MEDEZE Group Public Company Limited (MEDEZE), presented the Company’s business overview and first-quarter 2026 operating results at the listed companies’ Earnings Call (Opp Day), organized by the Stock Exchange of Thailand (SET).
For the first quarter of 2026, the Company reported total revenue of THB 176 million and demonstrated strong profitability growth. Gross profit margin increased by 5 percentage points from the previous quarter to 75%, reflecting the Company’s effective cost management capabilities and the strength of its core businesses in stem cell banking services and medical biotechnology.
In addition, MEDEZE continues to expand its franchise business model across the region. Its project in the Philippines serves as a successful prototype for the development of GMP-standard laboratory infrastructure, with plans to further expand its network into several countries across Asia and the Middle East.
At the same time, the Company is continuously advancing its Advanced Therapy Medicinal Products (ATMPs) business. MEDEZE is accelerating infrastructure development and research initiatives to support the growth of next-generation medical technologies and is currently driving the implementation of its ATMP Roadmap to strengthen its position in the future healthcare industry.
For more information, please visit: https://www.medezegroup.com/th/
IR Press Releases